Skip to main content

Table 5 Cox multivariable analysis for overall survival and cancer-specific survival stratified by p16 status

From: Association of pre-treatment lymphocyte-monocyte ratio with survival outcome in patients with head and neck cancer treated with chemoradiation

p16-negative cohort

 

Overall survival

Cancer-specific survival

aHR

95% CI

P

aHR

95% CI

P

LMR

 3.8 or higher

Reference

  

Reference

  

  < 3.8

0.87

0.42–1.83

0.72

1.28

0.50–3.31

0.61

p16-positive cohort

 

Overall survival

Cancer-specific survival

 

aHR

95% CI

P

aHR

95% CI

P

LMR

 3.8 or higher

Reference

  

Reference

  

  < 3.8

1.26

0.71–2.26

0.43

1.49

0.69–3.22

0.31

  1. LMR lymphocyte-monocyte ratio, aHR adjusted hazards ratio, 95% CI 95% confidence interval
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us